Presentation is loading. Please wait.

Presentation is loading. Please wait.

A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical.

Similar presentations


Presentation on theme: "A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical."— Presentation transcript:

1 A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence  Vivencio Barrios, Carlos Escobar, Arrigo Francesco Giuseppe Cicero, David Burke, Peter Fasching, Maciej Banach, Eric Bruckert  Atherosclerosis Supplements  Volume 24, Pages 1-15 (February 2017) DOI: /j.atherosclerosissup Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

2 Fig. 1 Complementary mechanisms of Armolipid Plus containing red yeast rice, policosanol, berberine, folic acid, astaxanthin, and coenzyme Q10. Atherosclerosis Supplements  , 1-15DOI: ( /j.atherosclerosissup ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

3 Fig. 2 Mean plasma concentrations for berberine (A) and lovastatin hydroxyl acid (B). SD are shown with vertical bar [38, modified]. Atherosclerosis Supplements  , 1-15DOI: ( /j.atherosclerosissup ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

4 Fig. 3 A. Comparison between Armolipid Plus and ezetimibe (10 mg daily) in 228 patients with primary hypercholesterolemia and intolerance to statins (22%) or refusal to take them (78%) within the setting of a 6-month randomized controlled clinical trial (p-values are for comparison between groups). B. Results of the treatment of 26 patients in whom monotherapy with Armolipid Plus (n = 14) or ezetimibe (10 mg daily) had failed (reduction in LDL-C plasma levels <29%) for another 3 months with the combination of Armolipid Plus + ezetimibe [53] (p-values are for comparison between the association of Armolipid Plus + ezetimibe and the single administration of the 2 compounds). Atherosclerosis Supplements  , 1-15DOI: ( /j.atherosclerosissup ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

5 Fig. 4 Variations in the primary endpoint (A) and in secondary endpoints (B) [44]. HOMA: Homeostasis model assessment; FMD: Flow-mediated dilation. Atherosclerosis Supplements  , 1-15DOI: ( /j.atherosclerosissup ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions


Download ppt "A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical."

Similar presentations


Ads by Google